RxDoctor Payments Data

Karen Figueredo Reyes

Family Medicine · Palmetto Bay, FLNPI 1740539394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Astrazeneca UK Limited at 33.9% of the total. Reporting peaked in 2022 at $186 and has fallen 56.4% since, to $81 in 2024. That places this record below the midpoint for family medicine clinicians in FL, where the typical reported total is $424.

$487in general payments, 2019–2025

Across 13 payments — averaging $37.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$165
  • AstraZeneca$151
  • Pfizer$137
  • Novartis$20
  • Lilly USA, LLC$15
$4,887,175in research payments, 2019–2025

Across 623 payments — averaging $7844.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$943K
  • Vanda Pharmaceuticals Inc.$625K
  • AbbVie$492K
  • Exeltis, USA Inc.$462K
  • Organon$442K
  • GSK$365K
  • plus $1.6M from 11 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited1$165
AstraZeneca2$151
Pfizer8$137
Novartis1$20
Lilly USA, LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$487 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$44,297
Rosuvastatin Calcium18$324
Gabapentin48$275
Omeprazole11$250
Cephalexin33$179
Vitamin D2Ergocalciferol (Vitamin D2)12$166
Ibuprofen15$151
Amlodipine Besylate28$112
Losartan Potassium13$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$15$44,29737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palmetto Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →